Literature DB >> 1647780

Hypophosphatasia and the extracellular metabolism of inorganic pyrophosphate: clinical and laboratory aspects.

A M Caswell1, M P Whyte, R G Russell.   

Abstract

Hypophosphatasia is a rare inherited disorder in which the activity of the bone/liver/kidney or tissue nonspecific form of alkaline phosphatase (ALP) is reduced. The clinical expression of the disease is highly variable, but in early life the severity tends to reflect the age of onset. Accordingly, the disease is often classified into perinatal, infantile, and childhood forms. Hypophosphatasia also occurs in adults. Some exhibit symptoms in adulthood for the first time, but others have a history of the disease in early life with an intervening symptom-free period. Defective mineralization of bones and teeth is the predominant clinical feature of all forms of the disease. Biochemically, the reduction in ALP activity is associated with alterations in the extracellular metabolism of various phosphorylated compounds, including inorganic pyrophosphate (PPi), phosphoethanolamine, and pyridoxal 5'-phosphate. Of these, PPi may have an especially important role in the development of the mineralization defect. Accordingly, the extracellular metabolism of PPi and its possible role in the regulation of mineralization will be discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1647780     DOI: 10.3109/10408369109106862

Source DB:  PubMed          Journal:  Crit Rev Clin Lab Sci        ISSN: 1040-8363            Impact factor:   6.250


  19 in total

1.  Autosomal dominant craniometaphyseal dysplasia is caused by mutations in the transmembrane protein ANK.

Authors:  E Reichenberger; V Tiziani; S Watanabe; L Park; Y Ueki; C Santanna; S T Baur; R Shiang; D K Grange; P Beighton; J Gardner; H Hamersma; S Sellars; R Ramesar; A C Lidral; A Sommer; C M Raposo do Amaral; R J Gorlin; J B Mulliken; B R Olsen
Journal:  Am J Hum Genet       Date:  2001-04-16       Impact factor: 11.025

2.  Hypophosphatasia.

Authors:  I J Ramage; A J Howatson; T J Beattie
Journal:  J Clin Pathol       Date:  1996-08       Impact factor: 3.411

Review 3.  Hypophosphatasia: clinical manifestation and burden of disease in adult patients.

Authors:  Francesco Conti; Lorenzo Ciullini; Giuseppe Pugliese
Journal:  Clin Cases Miner Bone Metab       Date:  2017-10-25

Review 4.  Hypophosphatasia.

Authors:  Agnès Linglart; Martin Biosse-Duplan
Journal:  Curr Osteoporos Rep       Date:  2016-06       Impact factor: 5.096

5.  Biochemical and genetic analysis of ANK in arthritis and bone disease.

Authors:  Kyle A Gurley; Richard J Reimer; David M Kingsley
Journal:  Am J Hum Genet       Date:  2006-10-16       Impact factor: 11.025

Review 6.  Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment.

Authors:  Michael P Whyte
Journal:  Nat Rev Endocrinol       Date:  2016-02-19       Impact factor: 43.330

7.  Asfotase alfa treatment for 1 year in a 16 year-old male with severe childhood hypophosphatasia.

Authors:  S A Bowden; B H Adler
Journal:  Osteoporos Int       Date:  2017-10-18       Impact factor: 4.507

8.  Matrix vesicles in osteomalacic hypophosphatasia bone contain apatite-like mineral crystals.

Authors:  H C Anderson; H H Hsu; D C Morris; K N Fedde; M P Whyte
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

9.  Alkaline phosphatase: placental and tissue-nonspecific isoenzymes hydrolyze phosphoethanolamine, inorganic pyrophosphate, and pyridoxal 5'-phosphate. Substrate accumulation in carriers of hypophosphatasia corrects during pregnancy.

Authors:  M P Whyte; M Landt; L M Ryan; R A Mulivor; P S Henthorn; K N Fedde; J D Mahuren; S P Coburn
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

10.  Different missense mutations at the tissue-nonspecific alkaline phosphatase gene locus in autosomal recessively inherited forms of mild and severe hypophosphatasia.

Authors:  P S Henthorn; M Raducha; K N Fedde; M A Lafferty; M P Whyte
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.